Complement factor H-related protein 1 (CFHL1) was recently reported to be a potential biomarker in several types of cancer. CFHL1, however, has not been found to be of prognostic value in hepatocellular carcinoma (HCC) to date. In the present study, the expression levels of CFHL1 were evaluated in 8 pairs fresh frozen tissue samples using western blotting. Furthermore, the expression level of CFHL1 was evaluated in 76 pairs of formalin-fixed, paraffin-embedded (FFPE) HCC and peritumoral tissues (expression pattern cohort), and 278 FFPE HCC tissues (prognostic cohort) using tissue microarray-based immunohistochemistry. The Kaplan-Meier method, Cox regression proportional hazard model and receiver operating characteristic curve analysis were used to evaluate prognostic factors. The expression level of CFHL1 was reduced in HCC tissues in 67.1% (51/76) of the cases compared with the corresponding peritumoral tissues. Survival analyses indicated that patients with HCC with low CFHL1 expression had a worse time-to-recurrence (TTR) and overall survival (OS) compared with those with high CFHL1 expression in the prognostic cohort (P=0.002 for OS and P=0.017 for TTR). Both univariate and multivariate analyses indicated that CHFL1 was an independent prognostic factor for TTR and OS (P=0.017 and P=0.002, respectively). In addition, The Cancer Genome Atlas (TCGA) and Human Protein Atlas were used for further validation. Furthermore, a prognostic model included tumor size, tumor number, liver cirrhosis and CFHL1 expression was evaluated. The results of the present study demonstrated that CFHL1 was downregulated in HCC and its level was associated with patient prognosis; therefore, CFHL1 is a potential prognostic marker for HCC.
Introduction
Liver resection is considered to be the most effective therapy for patients with hepatocellular carcinoma (HCC) to date. However, due to the high incidence of tumor recurrence and metastasis, the overall prognosis of HCC remains unsatisfactory (1) . It has been reported that >70% of patients with HCC develop recurrence within 5 years after surgery (2) . The mechanism underlying recurrence and metastasis of HCC is complex and remains unclear. Therefore, novel molecular prognostic biomarkers of HCC are required to improve the survival of patients with HCC (3). Complement factor H-related protein 1 (CFHL1), a member of the complement factor H (CFH) family, was demonstrated to inhibit the activity of C5 convertase, as well as the assembly and membrane insertion of the terminal complement components (4, 5) . It was also reported that human CFHL1, had a function and structure similar to human CFH (6) . Several studies reported that CFHR is associated with bladder cancer and may be used as a quantitative urinary tumor marker in selected patients (7, 8) . In 2011, Yang et al (9) revealed that CFH exhibited decreased mRNA expression and increased CpG site methylation in surgically resected HCC tissues; however, no further studies verified this result. Therefore, the aim of the present study was to investigate the potential prognostic value of CFHL1 in HCC. First, immunohistochemistry (IHC) and western blot analysis were used to evaluate CFHL1 protein levels in HCC and paired peritumoral tissues. Subsequently, the association between CFHL1 expression and overall survival (OS), pathological characteristics of HCC and time-to-recurrence (TTR) was analyzed and the prognostic value of CFHL1 for postoperative patients with HCC was determined via receiver operating characteristic (ROC) curves. (10) . The present study was approved by the Institutional Review Board of the Eastern Hepatobiliary Surgery Hospital and each patient provided written informed consent. FFPE specimens were divided into two groups, namely 76 specimens with paired peritumoral liver tissues and 278 specimens with prognostic data. All 278 cases with prognostic data were followed up after surgery every 3 months for the first year and every 6 months thereafter until December 2013. Serum α-fetoprotein (AFP) examination, abdominal ultrasonography and chest X-ray were performed monthly within the first year after surgery and every 3-6 months thereafter. Computed tomography scanning (CT) or magnetic resonance imaging (MRI) of the abdomen was performed every 6 months or immediately upon suspicion of recurrence. The criteria for recurrence were the same as the preoperative diagnostic criteria (11) . TTR was defined as the time between tumor resection and tumor recurrence, and OS was defined as the time between surgery and the date of the last follow-up or the date of mortality from any cause. Each FFPE tissue specimen was stained by hematoxylin and eosin and two experienced liver pathologists reviewed the stained sections. Sections (4-µm thick) were placed on slides coated with 3-aminopropyltriethoxysilane. Subsequently, samples were deparaffinized, washed twice with xylene (each 10 min) and rehydrated twice with 100% alcohol for 5 min each, once with 95% alcohol for 2 min and once with 70% alcohol for 2 min. Samples were washed with distilled water and stained with Harris hematoxylin solution for 6 min. Sections were washed under tap water for 5 min, differentiated in 1% acid alcohol for 10 sec, washed under tap water for 1 min and counterstained with eosin-phloxine solution for 30 sec. Subsequently, samples were dehydrated with 95 and 100% alcohol (each, 5 min), and washed twice with xylene (each, 5 min). Xylene based Neutral balsam was used to mount samples. All staining steps were performed at room temperature.
Immunohistochemistry, scoring and tissue microarray (TMA).
The method described by Kononen et al (12) was used for the TMAs. Briefly, two experienced pathologists reviewed HE-stained sections and then pre-marked the representative cores in the paraffin blocks. A 1.5-mm diameter tissue cylinder, which was subsequently incorporated into a recipient paraffin block, was punched from a marked area of each block. Subsequently, 4-mm sections were placed on slides coated with 3-aminopropyltriethoxysilane. The paraffin sections were deparaffinized in xylene and rehydrated through decreasing concentrations of ethanol (100, 95 and 85%; 5 min each). Antigens were retrieved by microwave irradiation for 5 min in citrate buffer (pH 6.0) and cooled at room temperature for 120 min, according to the protocol reported by Jin et al (13) with minor modifications (microwave irradiation was applied for 5 min in the current study, compared with 3 min in the previous study). The slides were incubated in 3% H 2 O 2 /phosphate-buffered saline to block endogenous peroxidase activity and non-specific binding sites were blocked with goat serum. Samples were treated with Rabbit polyclonal primary antibodies specific to CFHL1 (cat. no. for 5 min. Negative control slides were created for all assays by omission of the primary antibodies. As previously reported (14), the integrated optical density (IOD) of CFHL1 was considered to reflect the expression level. A Leica CCD camera DFC420 connected to a Leica DM IRE2 microscope (Leica Microsystems, Ltd., Milton Keynes, UK) was used for imaging. High-power magnification (x200) with Leica QWin Plus software (version 3; Leica Microsystems, Ltd.) was used to capture images of representative fields. The IOD of each image was counted and measured using Image-Pro Plus software (version 6.0; Media Cybernetics, Inc., Bethesda, MD, USA).
Western blot analysis. Another eight pairs of fresh frozen tissue samples were selected for western blotting which was performed as previously described (15) . Characteristics of patients the samples were collected from are summarized in Table I . Briefly, tissue samples were homogenized in a radioimmunoprecipitation assay buffer (Qiagen China Co., Ltd., Shanghai, China) with a cocktail of proteinase inhibitors (Roche Applied Science, Basel, Switzerland) and a cocktail of phosphatase inhibitors (Roche Applied Science). The protein concentrations were determined using the bicinchoninic acid kit (Pierce; Thermo Fisher Scientific Inc., Waltham, MA, USA 
Results

CFHL1 is downregulated in HCC tissues at the protein level.
Cytoplasmic expression of CFHL1 was detected in both HCC and peritumoral tissues (Fig. 1A-C) . The results demonstrated that CFHL1 expression was downregulated in 51 and upregulated in 25 HCC tissue samples, compared with the peritumoral tissue samples (P=0.0009; Fig. 1D ). Additionally, the expression level of CFHL1 was analyzed in 8 paired HCC and peritumoral tissue samples by western blotting. The expression level of CHFL1 was lower in HCC tissues compared with peritumoral samples; however, the difference was not statistically significant (Fig. 1) .
Association between clinicopathological characteristics and CFHL1 expression. In order to determine the association between CFHL1 expression and clinicopathologcal variables in patients with HCC, data from the 354 patients with HCC were collected and evaluated by χ 2 test. The results demonstrated that low CFHL1 expression was associated with vascular invasion (P=0.024) and serum AFP levels (P=0.039); however, no significant associations were observed with other clinicopathological parameters, including liver cirrhosis, sex, TNM stage, age, HBsAg, tumor size, Child-Pugh class, tumor differentiation or tumor number (all P>0.05; Table II ).
Association of low CFHL1 expression with OS and TTR in patients with HCC.
The association of low CFHL1 expression with OS and TTR was further assessed in 278 cases of HCC via univariate and multivariate analyses (Table III) . The results demonstrated that tumor size, liver cirrhosis, TNM stage, tumor number, CFHL1 expression and vascular invasion were significant prognostic factors for OS and TTR on univariate analysis (all P<0.05). With regard to tumor differentiation in the univariate analysis, there was a statistically significant difference for TTR (P=0.039), while there was no difference for OS (P=0.271). In the multivariate analysis, liver cirrhosis, tumor size, low CFHL1 expression and tumor number were independent prognostic factors for OS and TTR (all P<0.05). Furthermore, as presented in Fig. 2 , both OS and TTR were significantly worse in the low CFHL1 expression group (number of patients, 207) compared with those in the high CFHL1 expression group (n=71; all P<0.05).
Further validation in TCGA and The Human Protein Atlas datasets.
To validate the expression of CFHL1, CFHL1 mRNA expression data in 50 pairs of HCC and normal tissue samples were obtained from the database of The Cancer Genome Atlas (TCGA; cancergenome.nih.gov). Fig. 3A revealed that CFHL1 mRNA expression levels in 50 pairs of HCC were statistically lower compared with normal tissue samples (P=0.0195). CFHL1 mRNA expression level of 365 patients in The Human Protein Atlas dataset (www.proteinatlas.org) was used for prognosis validation. Results revealed that low CFHL1 mRNA level was associated with worse prognosis compared with the high-expression group (P=8.71x10 -6 ; Fig. 3B ). Table III , a new prognostic model was proposed that included liver cirrhosis, tumor size, tumor number and CFHL1 for both OS and TTR. As presented in Fig. 4 , the ROC curve analysis demonstrated that the predictive accuracy of the new prognostic model [area under the curve (AUC) 0.697 for OS and 0.702 for TTR] was higher compared with that for any other factor and the prognostic model without CFHL1 (liver cirrhosis/tumor number/tumor size combination). The AUC Table II . CFHL1 expression level associations with pathological characteristics of HCC. Based on HBsAg, the data of three patients are missing; Based on AFP, the data of two patients are missing; Based on Child-Pugh score, the data of one patient is missing. CFHL1, Complement factor H-related protein 1. 
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Discussion
The present study demonstrated that CFHL1 expression was decreased in HCC tissues, and patients with low CFHL1 expression exhibited worse OS and TTR. Furthermore, after proposing a new prognostic model, the AUC of this new model was higher compared with that of the liver cirrhosis/tumor size/tumor number combination. Collectively, these data indicated that decreased CFHL1 expression was associated with poor outcome in patients with HCC.
To the best of our knowledge, there are no studies in the literature on the association between CFHL1 and cancer, including HCC. In the current study, the expression of CFHL1 was examined in HCC and paired peritumoral tissues by western blot analysis and immunohistochemical examination. The results revealed that CFHL1 was downregulated in HCC tissues, with a significant difference between HCC and peritumoral tissues, indicating that CFHL1 may be a risk factor for HCC. In addition, based on the Kaplan-Meier analysis, an association was observed between CFHL1 protein expression and clinical outcome in patients with HCC after surgery. Patients with low CFHL1 expression had worse OS and shorter TTR compared with cases with high CFHL1 expression. The multivariate analysis indicated that CFHL1 was an independent postoperative predictor of recurrence and OS. Furthermore, in order to validate the prognostic value of decreased CFHL1 expression in postoperative patients with HCC, ROC curve analysis and bioinformatics analysis were performed. The results revealed that the new prognostic model was superior to that without CFHL1 (liver cirrhosis/tumor size/tumor number combination) and low CFHL1 mRNA level had worse prognosis, indicating that CFHL1 may be a reliable prognostic factor for postoperative patients with HCC.
To the best of our knowledge, the present study was the first to investigate the association between CFHL1 expression and the prognosis of postoperative patients with HCC, however, there were several limitations. First, similar studies on the role of CFHL1 in other types of cancer, which could expand the prognostic value of CFHL1, are required. Second, more in vivo and in vitro studies should be performed in the future to elucidate why the downregulated expression of CFHL1 is associated with unfavorable prognosis in postoperative HCC patients. Previous studies have demonstrated an association of CFHL1 with human neutrophil granulocytes (17) and the human immune system (18) .
In conclusion, the current study was the first to demonstrate that CFHL1 may be of high prognostic value in postoperative patients with HCC and it may be used as a new prognostic biomarker in such individuals. However, further studies, particularly on the association between CFHL1 and the tumor microenvironment, should be conducted in the future. 
